BioNTech Founders to Leave and Launch New mRNA Company

The Architects of the COVID Vaccine Move On

Ugur Sahin and Ozlem Tureci, the husband-and-wife team who co-founded BioNTech and led the development of one of the first COVID-19 vaccines, are set to leave the company by the end of 2026 to establish a new venture dedicated to next-generation mRNA technology. The departure marks the end of an era for BioNTech and raises questions about the future direction of one of biotechnology's most important companies.

BioNTech confirmed that the company will narrow its focus to its late-stage clinical pipeline following the founders' exit. This strategic shift suggests that BioNTech will become more of a conventional pharmaceutical company, advancing its existing drug candidates through clinical trials and toward market approval, while the founders pursue more exploratory mRNA research at their new entity.

Why the Founders Are Leaving

Sahin and Tureci are scientists by training and temperament. Before the pandemic catapulted BioNTech to global prominence, they had spent two decades working on mRNA-based cancer immunotherapies — a technically challenging field that had attracted limited commercial interest. The COVID vaccine brought sudden fame, enormous revenue, and the operational demands of managing a rapidly growing public company.

The decision to leave and start fresh reflects a desire to return to the frontier of mRNA science, free from the constraints of managing a large organization with obligations to public market shareholders. Their new company is expected to focus on areas where mRNA technology could be transformative but that require long-term research commitment — including personalized cancer vaccines, rare genetic diseases, and novel approaches to autoimmune conditions.

BioNTech Without Its Founders

BioNTech's post-founder identity will center on its existing pipeline, which includes several promising cancer therapy candidates in clinical trials. The company's mRNA-based individualized neoantigen-specific immunotherapy, or iNeST, has shown encouraging results in clinical studies for melanoma and pancreatic cancer when combined with checkpoint inhibitor drugs.

However, BioNTech faces significant headwinds. COVID vaccine revenue has declined dramatically as the pandemic has evolved into an endemic phase, and the company's attempts to diversify beyond COVID have not yet produced a commercially successful product. The loss of Sahin, who served as CEO and was the scientific visionary behind the company's technology platform, creates a leadership vacuum that will be difficult to fill.

The company will need to demonstrate that its pipeline can generate value independent of its founders' scientific reputation — a transition that many founder-led biotech companies struggle to navigate. Investors will be watching closely for signs that BioNTech's research culture and innovation capacity survive the transition.

The New Venture's Potential

While details of the new company remain scarce, Sahin and Tureci's track record makes it one of the most anticipated biotech launches in years. Their deep expertise in mRNA biology, combined with the wealth and connections generated by BioNTech's success, positions them to attract top scientific talent and significant funding.

The mRNA field has expanded enormously since the pandemic, with research groups and companies around the world exploring applications far beyond vaccines. Moderna, BioNTech's primary COVID vaccine competitor, is advancing mRNA programs in infectious diseases, oncology, and rare diseases. Smaller companies are exploring mRNA-based protein replacement therapies, gene editing delivery, and agricultural applications.

Sahin and Tureci's new venture could focus on technical frontiers that current companies have not yet addressed — such as mRNA molecules with extended stability, tissue-specific delivery systems that target particular organs with high precision, or combinatorial approaches that deliver multiple mRNA payloads simultaneously for complex diseases.

Impact on the mRNA Ecosystem

The departure creates ripple effects across the mRNA technology landscape. BioNTech's scientific team, many of whom were recruited based on the founders' reputation, may face uncertainty about the company's future direction. Some may follow Sahin and Tureci to the new venture, potentially depleting BioNTech's research capabilities while strengthening the newcomer.

For the broader biotechnology industry, the move underscores a recurring pattern: the founders who drive breakthrough innovations often find themselves poorly suited to managing the large organizations their breakthroughs create. The scientific creativity that produces transformative technologies operates best with the freedom to explore, fail, and pivot — conditions that are difficult to maintain in a public company managing billions in revenue and a complex clinical pipeline.

Market Reaction and Outlook

BioNTech's share price has been under pressure for months as COVID vaccine sales declined and investors questioned the company's ability to replicate its pandemic-era success. The founders' departure adds another layer of uncertainty, though the announcement that BioNTech will narrow its focus to late-stage clinical programs could eventually provide clearer valuation metrics for the remaining business. The pharmaceutical world will be watching both entities closely — one represents the maturation of mRNA technology into conventional drug development, while the other embodies the ongoing scientific frontier of what mRNA can achieve.

This article is based on reporting by endpoints.news. Read the original article.